首頁 > 市場調查報告書 > 醫療設備

生技設備

市場調查報告書

商品編碼

1811800

生物銀行市場 - 全球和區域分析：按產品和服務、儲存類型、樣本類型、所有者、生物銀行類型、應用、國家和地區的分析和預測（2025-2035年）

Biobanking Market - A Global and Regional Analysis: Focus on Product and Service, Storage Type, Sample Type, Ownership, Biobank Type, Application, Country, and Region - Analysis and Forecast, 2025-2035

出版日期: 2025年09月15日 | 出版商:

BIS Research | 英文 120 Pages | 商品交期: 1-5個工作天內

價格

簡介目錄圖表

生物銀行市場的主要成長要素之一是個人化醫療需求的不斷成長。

隨著基因組學和生物技術的進步，根據每位患者的基因資訊最佳化醫療保健的趨勢日益成長。生物樣本庫保存多樣化的生物樣本，以了解基因變異及其對健康和疾病的影響，開發更有效、副作用更少的標靶治療和治療方法。

此外，癌症、糖尿病和心血管疾病等慢性疾病的增加也推動了對生物樣本庫的需求。提供生物材料庫使研究人員能夠識別疾病的生物標記物，了解疾病機制，並開發新的診斷和治療方法。隨著個人化醫療成為現代醫學的核心支柱，對提供高品質生物樣本的生物樣本庫的需求預計將持續成長。

儘管生物銀行市場持續成長，但仍存在許多挑戰。其中最主要的挑戰之一是圍繞著生物樣本採集、儲存和使用的倫理和法律問題。知情同意、隱私以及捐贈者資訊的保密性等問題仍然是主要挑戰。尤其是在處理遺傳資訊等敏感資料時，樣本捐贈者提供知情同意並保護其隱私非常重要。

此外，不同地區和機構的生物銀行法規和標準化缺乏統一性，導致資料品質、樣本處理和儲存方面存在差異。這種標準化的缺乏使研究機構之間的資料共用和協作變得複雜，限制了生物樣本庫資源的全球效用。

最後，維護生物庫會帶來財務和基礎設施的挑戰：長期管理大量資料和樣本需要對儲存設施等實體基礎設施及其操作技術進行大量投資。

全球生物銀行市場最重要的新興趨勢之一是數位技術與自動化的融合。伴隨這一趨勢的是先進資料管理系統、人工智慧驅動平台以及樣本採集、儲存和分析自動化的引進。這些技術使生物銀行的運作更有效率、準確且擴充性，更易於管理大量生物樣本。自動化在維護樣本完整性方面發揮關鍵作用，它能夠簡化流程、減少人為錯誤並提高樣本處理的可靠性。

此外，數位化工具改善了不同實驗室和地區之間樣本的追蹤和管理，並促進了全球生物庫網路之間更有效的資料共用和協作。隨著對高品質、有組織的生物樣本的需求不斷成長，這一趨勢預計將繼續影響生物銀行產業，並支持個人化醫療、基因組學和藥物發現的進步。

本報告研究了全球生物銀行市場，並總結了主要趨勢、市場影響因素分析、法律制度、技術和專利分析、市場規模趨勢和預測、各個細分市場、地區/主要國家的詳細分析、競爭格局和主要企業的概況。

關鍵策略和發展
- M&A
- 協同活動
- 業務擴展和資金籌措
- 產品發布和核准
- 其他活動
公司簡介
- Becton, Dickinson and Company
- QIAGEN NV
- Merck KGaA
- Thermo Fisher Scientific Inc.
- PHC Holdings Corporation
- Cryoport, Inc.
- Azenta, Inc.
- Avantor, Inc.
- Tecan Trading AG
- Greiner AG
- Bay Biosciences LLC
- Shanghai Zhangjiang Biobank
- US Biolab Corporation, Inc.
- Cureline
- Brooks Life Sciences

第11章調查方法

簡介目錄圖表

Global Biobanking Market, Analysis and Forecast: 2025-2035

Biobanking refers to the process of collecting, storing, and managing biological samples (such as blood, tissue, DNA, RNA, and other bodily fluids) for research and medical purposes. These samples are preserved and catalogued in biorepositories or biobanks, where they are stored under controlled conditions to maintain their integrity for long-term use. Biobanks are invaluable resources for scientific research, particularly in fields like genomics, cancer research, drug development, and epidemiology.

Researchers use biobanks to investigate the genetic and environmental factors that contribute to diseases, understand disease mechanisms, and develop personalized treatments. Biobanks are also used for testing the efficacy of new medications, understanding population health trends, and advancing medical knowledge. With the growing focus on precision medicine, biobanks are becoming increasingly important as they provide high-quality biological samples that are essential for creating tailored healthcare solutions based on individual genetic profiles.

One of the key drivers of the biobanking market is the increasing demand for personalized medicine. As advancements in genomics and biotechnology continue to progress, there is a growing focus on tailoring medical treatments to individual patients based on their genetic makeup. Biobanks play a critical role in this area by storing diverse biological samples that can be used to understand genetic variations and their implications on health and disease. These samples help researchers develop targeted therapies and treatments that are more effective and less harmful to patients.

The rise in chronic diseases, such as cancer, diabetes, and cardiovascular conditions, further drives the need for biobanks. By providing a repository of biological materials, biobanks enable researchers to identify disease biomarkers, understand disease mechanisms, and develop new diagnostic and therapeutic methods. As personalized medicine becomes a central pillar of modern healthcare, the demand for biobanks and high-quality biological samples is expected to continue to grow.

Despite the growth of the biobanking market, several challenges persist. One of the primary challenges is the ethical and legal concerns associated with the collection, storage, and use of biological samples. Issues surrounding informed consent, privacy, and confidentiality of donor information remain a significant challenge. Ensuring that individuals provide informed consent for the use of their biological samples in research and that their privacy is protected is crucial, especially when dealing with sensitive genetic data.

Furthermore, the lack of uniform regulations and standardization in biobanking practices across different regions and institutions can lead to discrepancies in data quality, sample handling, and storage methods. This lack of standardization complicates data sharing and collaboration among research institutions, which can limit the global utility of biobank resources.

Lastly, there are financial, and infrastructure challenges related to maintaining biobanks, as they require significant investment in both the physical infrastructure (such as storage facilities) and technology to manage vast amounts of data and biological samples over extended periods.

The global Biobanking market is highly competitive, with major players such as Becton, Dickinson and Company, QIAGEN N.V., Merck KGaA, Thermo Fisher Scientific Inc., PHC Holdings Corporation, Cryoport, Inc., Azenta, Inc., Avantor, Inc., Tecan Trading AG, Greiner AG, Bay Biosciences LLC, Shanghai Zhangjiang Biobank, US Biolab Corporation, Inc., Cureline, and Brooks Life Sciences leading the way. These companies are continuously innovating and expanding their product portfolios to cater to the growing demand for biological sample storage, processing, and management in research, personalized medicine, and drug development.

The competition in the market is driven by advancements in technology, improvements in storage capabilities, and the increasing need for high-quality biological samples for clinical trials, genomic research, and disease study. With significant investments in infrastructure, digitalization, and regulatory compliance, these key players are well-positioned to shape the future of the biobanking market.

Biobanking Market Segmentation:

Segmentation 1: by Product and Service

Equipment
- Storage Equipment
- Sample Analysis Equipment
- Sample Processing Equipment
- Sample Transport Equipment
Consumables
- Storage Consumables
- Analysis Consumables
- Processing Consumables
- Collection Consumables
Services
- Storage Services
- Processing Services
- Transport Services
- Supply Services
Software

Segmentation 2: by Storage Type

Manual Storage
Automated Storage

Segmentation 3: by Sample Type

Blood Products
Human Tissues
Cell Lines
Nucleic Acids
Biological Fluids
Human Waste Products

Segmentation 4: by Ownership

Universities
National/Regional Agencies
Non-Profit Organizations
Private Organizations

Segmentation 5: by Biobank Type

Physical/Real Biobanks
Tissue Biobanks
Population-Based Biobanks
Genetic (DNA/RNA)
Disease-Based Biobanks
Virtual Biobanks

Segmentation 6: by Application

Regenerative Medicine
Life Science Research
Clinical Research

Segmentation 7: by End User

Pharmaceutical & Biotechnology Companies and Cros
Academic And Research Institutes
Hospitals

Segmentation 8: by Region

North America
Europe
Asia-Pacific
Rest of the World

One of the most significant emerging trends in the global biobanking market is the integration of digital technologies and automation. This trend involves the adoption of advanced data management systems, AI-driven platforms, and automation in sample collection, storage, and analysis. These technologies improve the efficiency, accuracy, and scalability of biobanking operations, making it easier to manage large volumes of biological samples. Automation helps streamline processes, reduces human error, and enhances the reliability of sample handling, which is crucial for maintaining sample integrity.

Moreover, digital tools enable better tracking and management of samples across different research facilities and regions, promoting more efficient data sharing and collaboration between global biobank networks. With the growing demand for high-quality and well-organized biological samples, this trend is expected to continue to shape the biobanking industry, supporting advancements in personalized medicine, genomics, and drug development.

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Biobanking Market: Industry Outlook

1.1 Introduction
1.2 Market Trends
1.3 Regulatory Framework
1.4 Case Studies
1.5 Product Benchmarking
1.6 Market Dynamics
- 1.6.1 Impact Analysis
- 1.6.2 Market Drivers
- 1.6.3 Market Challenges
- 1.6.4 Market Opportunities

2. Global Biobanking Market (by Product and Service), ($Billion), 2024-2035

2.1 Equipment
- 2.1.1 Storage Equipment
- 2.1.2 Sample Analysis Equipment
- 2.1.3 Sample Processing Equipment
- 2.1.4 Sample Transport Equipment
2.2 Consumables
- 2.2.1 Storage Consumables
- 2.2.2 Analysis Consumables
- 2.2.3 Processing Consumables
- 2.2.4 Collection Consumables
2.3 Services
- 2.3.1 Storage Services
- 2.3.2 Processing Services
- 2.3.3 Transport Services
- 2.3.4 Supply Services
2.4 Software

3. Global Biobanking Market (by Storage Type), ($Billion), 2024-2035

3.1 Manual Storage
3.2 Automated Storage

4. Global Biobanking Market (by Sample Type), ($Billion), 2024-2035

4.1 Blood Products
4.2 Human Tissues
4.3 Cell Lines
4.4 Nucleic Acids
4.5 Biological Fluids
4.6 Human Waste Products

5. Global Biobanking Market (by Ownership), ($Billion), 2024-2035

5.1 Universities
5.2 National/Regional Agencies
5.3 Non-Profit Organizations
5.4 Private Organizations

6. Global Biobanking Market (by Biobank Type), ($Billion), 2024-2035

6.1 Physical/Real Biobanks
6.2 Tissue Biobanks
6.3 Population-Based Biobanks
6.4 Genetic (DNA/RNA)
6.5 Disease-Based Biobanks
6.6 Virtual Biobanks

7. Global Biobanking Market (by Application), ($Billion), 2024-2035

7.1 Regenerative Medicine
7.2 Life Science Research
7.3 Clinical Research

8. Global Biobanking Market (by End User), ($Billion), 2024-2035

8.1 Pharmaceutical & Biotechnology Companies and Cros
8.2 Academic And Research Institutes
8.3 Hospitals

9. Global Biobanking Market (by Region), ($Billion), 2024-2035

9.1 North America
- 9.1.1 Key Findings
- 9.1.2 Market Dynamics
- 9.1.3 Market Sizing and Forecast
  - 9.1.3.1 North America Biobanking Market, by Country
    - 9.1.3.1.1 U.S.
    - 9.1.3.1.2 Canada
9.2 Europe
- 9.2.1 Key Findings
- 9.2.2 Market Dynamics
- 9.2.3 Market Sizing and Forecast
  - 9.2.3.1 Europe Biobanking Market, by Country
    - 9.2.3.1.1 Germany
    - 9.2.3.1.2 U.K.
    - 9.2.3.1.3 France
    - 9.2.3.1.4 Italy
    - 9.2.3.1.5 Spain
    - 9.2.3.1.6 Rest of the Europe
9.3 Asia Pacific
- 9.3.1 Key Findings
- 9.3.2 Market Dynamics
- 9.3.3 Market Sizing and Forecast
  - 9.3.3.1 Asia Pacific Biobanking Market, by Country
    - 9.3.3.1.1 China
    - 9.3.3.1.2 Japan
    - 9.3.3.1.3 India
    - 9.3.3.1.4 Australia
    - 9.3.3.1.5 Rest of Asia Pacific
9.4 Rest of the World
- 9.4.1 Key Findings
- 9.4.2 Market Dynamics
- 9.4.3 Market Sizing and Forecast

10. Global Biobanking Market: Competitive Landscape and Company Profiles

10.1 Key Strategies and Development
- 10.1.1 Mergers and Acquisitions
- 10.1.2 Synergistic Activities
- 10.1.3 Business Expansions and Funding
- 10.1.4 Product Launches and Approvals
- 10.1.5 Other Activities
10.2 Company Profiles
- 10.2.1 Becton, Dickinson and Company
  - 10.2.1.1 Overview
  - 10.2.1.2 Top Products / Product Portfolio
  - 10.2.1.3 Top Competitors
  - 10.2.1.4 Target Customers/End-Users
  - 10.2.1.5 Key Personnel
  - 10.2.1.6 Analyst View
- 10.2.2 QIAGEN N.V.
  - 10.2.2.1 Overview
  - 10.2.2.2 Top Products / Product Portfolio
  - 10.2.2.3 Top Competitors
  - 10.2.2.4 Target Customers/End-Users
  - 10.2.2.5 Key Personnel
  - 10.2.2.6 Analyst View
- 10.2.3 Merck KGaA
  - 10.2.3.1 Overview
  - 10.2.3.2 Top Products / Product Portfolio
  - 10.2.3.3 Top Competitors
  - 10.2.3.4 Target Customers/End-Users
  - 10.2.3.5 Key Personnel
  - 10.2.3.6 Analyst View
- 10.2.4 Thermo Fisher Scientific Inc.
  - 10.2.4.1 Overview
  - 10.2.4.2 Top Products / Product Portfolio
  - 10.2.4.3 Top Competitors
  - 10.2.4.4 Target Customers/End-Users
  - 10.2.4.5 Key Personnel
  - 10.2.4.6 Analyst View
- 10.2.5 PHC Holdings Corporation
  - 10.2.5.1 Overview
  - 10.2.5.2 Top Products / Product Portfolio
  - 10.2.5.3 Top Competitors
  - 10.2.5.4 Target Customers/End-Users
  - 10.2.5.5 Key Personnel
  - 10.2.5.6 Analyst View
- 10.2.6 Cryoport, Inc.
  - 10.2.6.1 Overview
  - 10.2.6.2 Top Products / Product Portfolio
  - 10.2.6.3 Top Competitors
  - 10.2.6.4 Target Customers/End-Users
  - 10.2.6.5 Key Personnel
  - 10.2.6.6 Analyst View
- 10.2.7 Azenta, Inc.
  - 10.2.7.1 Overview
  - 10.2.7.2 Top Products / Product Portfolio
  - 10.2.7.3 Top Competitors
  - 10.2.7.4 Target Customers/End-Users
  - 10.2.7.5 Key Personnel
  - 10.2.7.6 Analyst View
- 10.2.8 Avantor, Inc.
  - 10.2.8.1 Overview
  - 10.2.8.2 Top Products / Product Portfolio
  - 10.2.8.3 Top Competitors
  - 10.2.8.4 Target Customers/End-Users
  - 10.2.8.5 Key Personnel
  - 10.2.8.6 Analyst View
- 10.2.9 Tecan Trading AG
  - 10.2.9.1 Overview
  - 10.2.9.2 Top Products / Product Portfolio
  - 10.2.9.3 Top Competitors
  - 10.2.9.4 Target Customers/End-Users
  - 10.2.9.5 Key Personnel
  - 10.2.9.6 Analyst View
- 10.2.10 Greiner AG
  - 10.2.10.1 Overview
  - 10.2.10.2 Top Products / Product Portfolio
  - 10.2.10.3 Top Competitors
  - 10.2.10.4 Target Customers/End-Users
  - 10.2.10.5 Key Personnel
  - 10.2.10.6 Analyst View
- 10.2.11 Bay Biosciences LLC
  - 10.2.11.1 Overview
  - 10.2.11.2 Top Products / Product Portfolio
  - 10.2.11.3 Top Competitors
  - 10.2.11.4 Target Customers/End-Users
  - 10.2.11.5 Key Personnel
  - 10.2.11.6 Analyst View
- 10.2.12 Shanghai Zhangjiang Biobank
  - 10.2.12.1 Overview
  - 10.2.12.2 Top Products / Product Portfolio
  - 10.2.12.3 Top Competitors
  - 10.2.12.4 Target Customers/End-Users
  - 10.2.12.5 Key Personnel
  - 10.2.12.6 Analyst View
- 10.2.13 US Biolab Corporation, Inc.
  - 10.2.13.1 Overview
  - 10.2.13.2 Top Products / Product Portfolio
  - 10.2.13.3 Top Competitors
  - 10.2.13.4 Target Customers/End-Users
  - 10.2.13.5 Key Personnel
  - 10.2.13.6 Analyst View
- 10.2.14 Cureline
  - 10.2.14.1 Overview
  - 10.2.14.2 Top Products / Product Portfolio
  - 10.2.14.3 Top Competitors
  - 10.2.14.4 Target Customers/End-Users
  - 10.2.14.5 Key Personnel
  - 10.2.14.6 Analyst View
- 10.2.15 Brooks Life Sciences
  - 10.2.15.1 Overview
  - 10.2.15.2 Top Products / Product Portfolio
  - 10.2.15.3 Top Competitors
  - 10.2.15.4 Target Customers/End-Users
  - 10.2.15.5 Key Personnel
  - 10.2.15.6 Analyst View

11. Research Methodology

簡介目錄圖表

List of Figures

Figure: Global Biobanking Market (by Product and Service), $Billion, 2024 and 2035
Figure: Global Biobanking Market (by Storage Type), $Billion, 2024 and 2035
Figure: Global Biobanking Market (by Sample Type), $Billion, 2024 and 2035
Figure: Global Biobanking Market (by Ownership), $Billion, 2024 and 2035
Figure: Global Biobanking Market (by Biobank Type), $Billion, 2024 and 2035
Figure: Global Biobanking Market (by Application), $Billion, 2024 and 2035
Figure: Global Biobanking Market (by End User), $Billion, 2024 and 2035
Figure: Global Biobanking Market (by Region), $Billion, 2024 and 2035
Figure: Global Biobanking Market Key Trends, Analysis